Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Currently submitted to: Interactive Journal of Medical Research

Date Submitted: Aug 25, 2026
Open Peer Review Period: Sep 16, 2026 - Nov 11, 2026
(closed for review but you can still tweet)

NOTE: This is an unreviewed Preprint

Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).

Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.

Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).

Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.

Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.

Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Estimated Glomerular Filtration Rate in Diabetic versus Non-Diabetic Chronic Kidney Disease Patients

  • Ashraf Hassan Abd El Mobdy; 
  • Iman I. Sarhan; 
  • Reem M. Mansour; 
  • Hussein S. Hussein

ABSTRACT

Background:

Chronic kidney disease (CKD) constitutes a prominent issue in global public health challenges, commonly caused by diabetes. Sodium glucose co-transporter 2 (SGLT2) inhibitors provide both renal and cardiovascular preservation in addition to lowering blood glucose levels.

Objective:

The purpose of the study was to compare the influence of SGLT2 inhibitors on renal function, as measured by eGFR, in Diabetic type II CKD individuals and non-diabetic CKD individuals.

Methods:

This case-control study was done on 60 adult CKD individuals with stage 3 and 4 (eGFR>_20ml/min/1.73 m2) according to the KIDGO classification at Ain Shams University Hospitals, Cairo, Egypt. This study was executed on 60 adult CKD individuals with stage 3 and 4 (eGFR>_20ml/min/1.73 m2) according to the KIDGO classification. Participants were placed into two equal groups (GPs): GP I: CKD with T2DM and GP II: CKD and non-DM.

Results:

Mean percentage change in SBP and DBP, weight, eGFR, HbA1c, and ACR were comparable without significant differences between the groups. eGFR was comparable without a significant difference between the two groups. HbA1c was significantly higher in GP I than in GP II (P<0.001). There was a significant rise in eGFR, HbA1c, and ACR at baseline compared to after 24 weeks (P<0.001).

Conclusions:

SGLT2 inhibitors have been unequivocally demonstrated in this study to improve kidney-related outcomes in individuals with CKD and DKD. Furthermore, they optimize glomerular hemodynamic performance function and glycemic control, while significantly declining proteinuria and attenuating the progression of CKD. Clinical Trial: The study was registered at clinicaltrials.gov on 1 October 2024 (ID: NCT07302464).


 Citation

Please cite as:

Abd El Mobdy AH, Sarhan II, Mansour RM, Hussein HS

Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Estimated Glomerular Filtration Rate in Diabetic versus Non-Diabetic Chronic Kidney Disease Patients

JMIR Preprints. 25/08/2026:110277

DOI: 10.2196/preprints.110277

URL: https://preprints.jmir.org/preprint/110277

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.